Fig. 3From: Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progressionImpact of rSOST treatment on peripheral disease progression. There was no difference in the progression of peripheral disease between SOST treated and control mice. Scoring commenced prior to the first rSOST injection (Day 0). rSOST treated mice in red, control mice in blackBack to article page